Verrica Pharmaceuticals
VRCA
60 hedge funds and large institutions have $105M invested in Verrica Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 10 closing their positions.
0.1% less ownership
Funds ownership: 4.28% → 4.18% (-0.1%)
6% less funds holding
Funds holding: 64 → 60 (-4)
20% less capital invested
Capital invested by funds: $132M → $105M (-$26.7M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
50% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 20
70% less call options, than puts
Call options by funds: $9K | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$565K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$541K |
| 3 |
Two Sigma Investments
New York
|
+$139K |
| 4 |
State Street
Boston,
Massachusetts
|
+$129K |
| 5 |
Morgan Stanley
New York
|
+$126K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MML Investors Services
Springfield,
Massachusetts
|
-$664K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$478K |
| 3 |
JGC
J. Goldman & Co
New York
|
-$447K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$351K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$282K |
VRCA Hedge Fund Activity: Q1 2024 in Review
60 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q1 2024, worth a combined $105M — down 20% from $132M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of VRCA and 7 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 10 added.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $565K. The largest seller was MML Investors Services, cutting an estimated $664K.
- 60 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q1 2024, down from 64 in Q4 2023.
- Funds reported $105M of Verrica Pharmaceuticals stock for Q1 2024, down 20% quarter-over-quarter.
- 7 funds opened new Verrica Pharmaceuticals positions in Q1 2024 and 10 closed out, a net change of -3 holders.
- The largest Verrica Pharmaceuticals buyer in Q1 2024 was Wellington Management Group, an estimated $565K added.
- The largest Verrica Pharmaceuticals seller in Q1 2024 was MML Investors Services, an estimated $664K sold.
Based on aggregated 13F filings for Q1 2024.